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The electrophysiologic effects of the antiar-
rhythmic drugs, presented elsewhere in this sym-
posium, form only one of the bases for the selec-
tion of a therapeutic agent in any given clinical 
situation. The final choice depends at least on the 
following factors: 
1. The specific arrhythmia 
2. Underlying heart disease, if any 
3. The degree of compromise of the circula-
tion, if any 
4. The etiology of the arrhythmia 
5. The efficacy of the drug for that arrhythmia 
due to that etiology 
6. The toxicity of the drug, especially in the 
given patient with possible alterations in 
volume of distribution, biotransformation, 
and excretion 
7. The electrophysiologic effects of the drug 
8. The routes and frequency of administration 
available for that drug 
As no one drug meets, or even approaches, 
the criteria for the ideal antiarrhythmic, a knowl-
edge of several drugs is essential. Unfortunately, 
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adequate, controlled clinical comparisons are virtu-
ally nonexistent. 
A complete presentation of the non-electro-
physiologic pharmacology would include the follow-
ing considerations: 
1. Absorption and peak effect times 
2. Biotransformation 
3. Rate of elimination or half-life (t1d 
4. Drug interactions 
5. Toxicity 
6. Clinical usefulness 
7. Therapeutic drug levels 
8. Dosage schedules 
As all of the above data cannot be presented in 
the limited space available, only selected items will 
be discussed. Much of the preceding information 
is available, however, in standard texts ( 1 7, 10). 
(See Addendum 1) 
Quinidine. Quinidine is principally trans-
formed in the liver by hydroxylation, but some 10-
50% is excreted unchanged in the urine. This var-
iation in the quantity excreted in the urine is of 
considerable importance, and it is influenced by 
both glomerular filtration and by urine pH. 
Bell et et al. ( 3) measured the serum levels 
of quinidine in three groups of ten subjects after 
600 mg of oral quinidine. Normal subjects had, af-
53 
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ter two hours, significantly lower serum quinidine 
levels than the subjects with congestive heart failure 
( creatinine clearances of 35-80 ml per minute), or 
the subjects with renal disease and azotemia. While 
this study does not consider alterations in the volume 
of distribution, liver function, and so forth, the cor-
relation between the peak level of quinidine and 
the rate of fall of the serum levels with glomerular 
filtration is evident. Thus, we must consider renal 
function much in the same way as when we use 
digoxin. 
In addition to renal function, the pH of the 
urine is important in the excretion of quinidine. As 
urine pH rises, more of the urinary tubular quinidine 
is nonionized and, hence, more readily passes across 
the tubular epithelium, thus decreasing the quantity 
of filtered quinidine excreted in the urine. 
Figure 1 is taken from the study of Gerhardt et al. 
(9). In normal subjects, urine pH was raised 
by administering acetazolamide and sodium bicar-
bonate. As shown, serum quinidine levels rise as ur-
ine pH increases and, furthermore, the pharmaco-
logic significance of the higher serum quinidine 
levels is indicated by progressive increase in the Q-
T interval. 
Molar sodium lactate has been recommended as 
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a means of treating the arrhythmic abnormalities as-
sociated with quinidine toxicity. While such alkal-
izing therapy may improve the arrhythmias, it surely 
will also delay the excretion of quinidine and 
might prolong the duration of the toxicity. Also a 
large segment of the population has been consum-
ing a very effective urinary acidifier, ascorbic acid, in 
a huge dose. The doses of quinidine needed to es-
tablish an antiarrhythmic effect might be titrated 
in such an individual, who then discontinues the 
ascorbic acid . A considerable increase in serum 
quinidine could occur with a significant chance of 
serious toxicity. 
Thus the physician must consider glomerular 
filtration rate and urine pH when prescribing quini-
dine. Alterations in liver function and the apparent 
volume of distribution are probably also important 
but less quantifiable. 
The serum half-life (t112 ) is known for all of 
the available antiarrhythmic drugs, and this simpli-
fied concept is useful in understanding the necessity 
for loading doses, the frequency of dosing, the dur-
ation of toxicity, and the timing of clinical observa-
tions of the patient. 
The serum half-life is defined as the time re-
quired to reduce the serum level of a drug to one-
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Fig. I- Change of serum quinidine and change of ratio of measured Q-T interval to the maximum normal Q-T interval at measured 
heart rate (expression of quinidine effect), plotted relative to urine pH, for two subjects. (Reproduced by permission of Annals of 
Internal Medicine, 71 :929, 1969, and R. E. Gerhardt). 
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half its initial level. As the great majority of drugs 
follow first-order kinetics (the amount eliminated 
is proportional to the quantity present), the follow-
ing "rules" of half-life are widely applicable: 
1. The serum half-life is independent of the 
quantity of drug present. In figure 2, the 
disappearance curve declines 50% each 
half-life, decreasing from 100% to 50% 
the first half-life, from 50% to 25% the 
second half-life, and so forth. 
2. The half-life concept is independent of the 
mechanism of elimination ; urinary or intes-
tinal excretion, hepatic transformation, and 
so forth . 
3. The dosing interval must be shorter than 
the half-life to avoid wide fluctuations in 
serum levels and body stores of a drug. 
4. Essentially complete elimination of a drug 
is achieved after five half-lives and con-
versely, with regular dosing, at frequencies 
of the half-life, or more often, equilibrium 
levels are achieved after five half-lives (see 
accumulation curve) . After 3.3 half-lives, 
90% of equilibrium levels are achieved. This 
would then be an appropriate time to make 
clinical observations on the pharmacologic 
effects of the drug. 
For quinidine, the half-life is about 4-6 hours . 
Doctors Richardson, Zee, and Wyso (21) from our 
institution reported on studies in which quinidine 
was given at 9 A.M., 1, 5, and 9 P .M. While the serum 
levels before the next day's dose were still adequate, 
they were achieved at the expense of excessive 
levels one and one-half hours after the 9 P.M. dose. 
A six-hour schedule would have avoided the poten-
tially toxic levels at bedtime. 
In a study to be described further . below, 
Bloomfield et al. (7) gave patients quinidine 300 
mg at 0, 3, and 6 hours, as a loading attempt and 
then gave 300 mg every 6 hours thereafter. Fig-
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Fig. 2-The accumulation and disappearance of a drug is 
depicted in terms of its half-life. 
ure 3 shows that the serum concentrations did not 
reach equilibrium levels until after 24 hours, in 
keeping with the principles noted above. 
In summary, application of the rules of t112 
to quinidine suggests that where prompt action is 
needed, a loading dose should be given and that 
quinidine should be given every six hours to avoid 
peaks and troughs of serum levels and associated 
toxicity and subtherapeutic concentrations. 
"Quinidine Syncope" is the name employed 
by Selzer and Wray (23) to describe recurrent 
ventricular fibrillation, usually self-terminating, seen 
in patients treated with quinidine. It usually occurs 
after the first few doses, and it may be noted in 
patients with normal or even low serum quinidine 
levels. While tachyarrhythmias and ventricular fibril-
lation are well-known toxic effects of quinidine, these 
individuals seem to be unusually susceptible to this 
serious adverse effect. While most patients receiving 
quinidine have underlying heart disease, quinidine 
syncope can occur in patients with no detectable 
organic heart disorder. 
Some clinicians are attempting close monitoring 
of patients during the initiation of quinidine therapy. 
The effectiveness of such monitoring will be diffi-
cult to assess because of the infrequency of this syn-
drome. Selzer and Wray estimated that 3-5% of 
patients treated with quinidine may develop this 
idiosyncratic toxicity, but Bjerkelund (6) reported 
only l + % and Lown ( 16) reported only 0.5% 
sudden deaths in his series of 650 patients. 
Finally, in regard to quinidine, some note of 
its efficacy need be made. Bloomfield et al. (7) stud-
ied 53 patients with acute myocardial infarction in a 
placebo controlled, randomly allocated prospective 
HOURS AFTER ENTRY 
Fig. 3-Blood quinidine concentrations at various intervals 
during five days of prophylactic quinidine thera,py in 27 
patients with acute myocardial infarction. (Reproduced by 
permission of the New England Journal of Medicine, 285 : 
981, 1971, and S.S. Bloomfield) . 
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trial of oral quinidine ( vide supra). Because of the 
lag in achieving therapeutic serum quinidine levels, 
there was no difference between the treated and 
placebo groups in the first six hours, but thereafter 
(see fig. 4), there was a statistically significant re-
duction in premature ventricular and supraventricu-
lar contractions and in "serious ventricular arrhyth-
mias." As has also been true of the studies of other 
antiarrhythmics in acute myocardial infarction, there 
was no difference in mortality between the treated 
and control groups. 
Beta Adrenergic Receptor Blockers. The se-
rum half-life of oral propranolol (Inderal®) is 3-4 
hours. Successful management with less frequent 
dosing intervals is likely due to the fact that the 
large doses used result in blood levels which remain 
above the therapeutic level for a longer period of 
time. 
The major concern in beta-blocker therapy is 
the marked cardiovascular depression which these 
agents induce. In three separate series of dogs, we 
(19) determined the mean doses of three antiar-
rhythmic drugs required to convert ouabain (a car-
diac glycoside)-induced ventricular tachycardia to 
normal sinus rhythm. Alprenolol is an effective 
beta-blocker, the dose of which (intravenously) 
does not differ from propranolol. These doses of the 
three antiarrhythmics were then studied in a new 
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Fig. 4-0ccurrence of arrhythmias during five days of 
prophylactic quinidine or placebo therapy in 53 patients 
with acute myocardial infarction. (Reproduced by permis-
sion of the New England Journal of Medicine, 285:984, 
1971, and S.S. Bloomfield). 
series of paced, open chest dogs, and the electrocar-
diographic and hemodynamic effects of these drugs 
given in "equi-antiarrhythmic" doses are depicted 
in figure 5. The beta-blocker significantly pro-
longed the P-R and Q-T intervals and depressed 
blood pressure, cardiac output (aortic flow via an 
electromagnetic flow transducer), and left ventric-
ular contractility ( dp/ dt, peak left ventricular 
rate of pressure rise). Directionally similar but less 
marked alterations occurred with procainarnide, while 
diphenylhydantoin did not affect these or any of 
the other measured cardiovascular functions. Beta-
blockers are, therefore, the most likely of the antiar-
rhythmics to induce cardiac depression, and even in 
low doses, a worsening of heart failure or the pre-
cipitation of pulmonary edema may result. While it 
is true that the correction of an arrhythmia by the 
beta-blocker may so improve the heart's overall 
function as to counteract any direct myocardial de-
pression, such therapy is fraught with the danger that 
should the beta-blocker not affect the arrhythmia, 
its negative inotropic action will still be manifest. 
Except where an arrhythmia is caused by 
adrenergic mechanisms, beta-blockers are best 
avoided in patients with myocardial disease unless 
other therapy has failed and the situation is desper-
ate. 
Diphenylhydantoin. Diphenylhydantoin (DPH) is 
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RESPONSES TO "EQUIANTIARRHYTHMIC" DOSES 
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Fig. 5-The responses to equi-antiarrhythmic doses of 
alprenolol, diphenylhydantoin, and procainamide are shown. 
Statistically significant (P < .05) changes from control are 
indicated. (Reproduced by permission of Archives Inter-
nationales de Pharmacodynamie et de Therapie, 190:354, 
1971, and J. D . Proctor). 
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of particular interest. The differences in its electto-
physiologic effects have already been noted else-
where. Also, any consideration of DPH must include 
information about its pharmacokinetics and bio-
transformation. 
Diphenylhydantoin is slowly absorbed by 
mouth, peak levels not being achieved for hours. 
This drug should not be given intramuscularly sirice 
its absorption is erratic. Even intravenously, DPH 
effect requires 1-5 minutes , and rapid (bolus) in-
jections must be avoided. 
The biotransformation of DPH is shown in fig-
ure 6. Diphenylhydantoin is parahydroxylated by 
oxidizing enzymes in the liver microsomes, convert-
ing DPH to HPPH (hydroxyphenyl, phenylhydan-
toin or 5 phenyl 5'parahydroxyphenylhydantoin). 
It is this enzyme which is so susceptible to both en-
zyme inhibition and enzyme induction, accounting 
for the large number of reported DPH drug inter-
actions (see addendum 2). Hydroxyphenyl, phenyl-
hydantoin, the inactive metabolite, is conjugated with 
glucuronide, and its excretion in the urine normally 
accounts for about 75% of the elimination of 
DPH. Letteri et al. (15) have found that patients 
with uremia have lower serum levels of DPH than 
do normal subjects receiving the same dose, and 
that furthermore, the t112 in uremia is shorter (more 
rapid DPH disappearance). This, of course, is quite 
the opposite from most drugs where renal failure 
results in higher serum levels and longer t11 2 . The 
mechanism whereby lower DPH levels are seen in 
uremia has not been completely elucidated, but 
several possible mechanisms have been suggested. 
It is known that HPPH levels are higher in uremic 
patients. It might be that something in the uremic 
state induces the parahydroxylating enzyme, hence 
more rapidly converting DPH to HPPH, or it may be 
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Fig. 6-Major route of metabolism of DPH. (Reproduced 
by permission of the New England Journal of Medicine, 
285: 651, and Joseph M. Letteri). 
that the renal failure blocks the excretion of HPPH 
which competes with DPH for serum protein binding 
sites (see fig. 6). The unbound, free DPH would 
be more accessible to enzymatic conversion to 
HPPH and also more accessible to its receptor site. 
Thus, while total DPH would be reduced, the free 
(active) portion might be normal. Finally, it is 
known that serum protein binding is altered in ure-
mia and this, too, could account for the lower total 
DPH and its more rapid conversion to HPPH due to 
more of the serum DPH existing in the free, un-
bound form. 
The clinical role of DPH is receiving more 
attention. Lown and Wolf (16) report studies in 
which ventricular fibrillation was induced in dogs 
by occluding, and if necessary, later releasing the 
occlusion, of the anterior descending coronary ar-
tery. About 75 % of untreated dogs developed ven-
tricular fibrillation, and pretreatment with DPH 
had no effect. On the other hand, pretreatment with 
procainamide reduced the incidence of ventricular 
fibrillation to about 20%; quinidine, lidocaine, 
practolol (a beta-blocker), and bretylium tosylate 
reduced it to about 3 5 % ; and dextro-propranolol and 
ajmaline reduced ventricular fibrillation to about 
50 %. 
Last year an Australian cooperative group re-
ported a clinical trial of DPH prophylaxis in patients 
discharged from the hospital after their first acute 
myocardial infarction (8). Diphenylhydantoin, 300-
400 mg per day, was given to 283 patients while the 
control group received 3-4 mg per day. Although 
the high dose DPH group had less palpitations and 
less documented arrhythmias than the control group, 
survival was unaffected. 
Mercer and Osborne (18) in 1967, noted that 
the etiology of the arrhythmia was a significant fac-
tor in predicting its response to DPH. Where the 
arrhythmia was due to digitalis intoxication, one-
half of the patients were successfully managed with 
DPH, but where the arrhythmia was due to coro-
nary heart disease, only about one-fourth re-
sponded. (These percentages may not represent 
the maximum efficacy of DPH as the dosage sched-
ules suggested below were not employed.) 
From these data, it would appear that digitalis 
intoxication is the prime indication for DPH and 
that its usefulness in coronary heart disease is likely 
to be limited. 
The effective serum concentration of DPH was 
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established by the elegant studies of Bigger and 
his colleagues (5) (fig. 7) . These data indicate an 
effective level of about 6-18 µg per ml, the same 
range as that established for anti-convulsant efficacy 
(10-20 µg per ml). 
Diphenylhydantoin does not follow first-order 
kinetics as even usual doses approach saturation of 
the parahydroxylating enzyme system. Thus, the 
"rules" of half-life do not, strictly speaking, apply 
to DPH. In the effective serum level range, how-
ever, DPH serum levels decline by one-half over 
18-24 hours. It is evident then, that without a load-
ing dose, several days will be needed to achieve 
equilibrium levels. Kutt and McDowell ( 14) and 
Bigger et al. ( 5) have recommended the following 
dose schedule for prompt DPH effect: 
Day Dose (mg) 
1 1,000 
2 500-600 
3 500-600 
Thereafter 400-500 
Where urgent indications exist, DPH may be 
given intravenously, 50-100 mg at 5 minute intervals 
until a therapeutic effect, a toxic effect, or 1,000 mg 
is given ( 5) . If less than 1,000 mg is given IV, the 
NUMBER OF 
PAT IENTS 
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Fig. 7-Plasma levels at which ventricular arrhythmias 
were abolished. Plasma DPH concentrations are plotted 
on the abscissa. The number of patients whose arrhythmia 
was abolished in each range of plasma level is represented 
on the ordinate as unfilled bars. The one patient whose 
arrhythmia was unaffected by DPH is represented by the 
filled bar; this unresponsive arrhythmia was a typical ven-
tricular parasystole. Seventy percent of the conversions oc-
curred at plasma concentrations between 1 O and 18 
µg / ml. Only one patient required a plasma concentration 
above 18 µg / ml before conversion occurred. (Reproduced 
by permission of the American Heart Association from 
Circulation , 38:367, 1968, and J . T. Bigger, Jr.). 
rest of the loading dose may be given slowly IV 
or orally over the next 6-18 hours. Where less 
urgency exists, the 1,000 mg should be given orally 
over 6-18 hours . 
One last point needs to be made in regard to 
DPH. This is one of the very few currently avail-
able drugs for which generic non-equivalence exists. 
(Digoxin is the other important example.) Generic 
brands of DPH have been shown to result in higher 
serum levels than the first marketed product, Dil-
antin®. An "epidemic" of DPH toxicity occurred 
when the source of supply of DPH was changed to 
a generic product and its greater bioavailability re-
sulted in toxic effects in previously stable patients 
with convulsive disorders (25). Patients on DPH 
should receive a single manufacturer's product. 
Bretylium Tosylate. Bretylium tosylate, BT, is 
a drug of considerable current interest. It is avail-
able only on an investigational basis , viz., it is not 
approved for marketing in this country. 
Much of the action of bretylium can be under-
stood in light of its effects on the sympathetic neu-
ron. Norepinephrine is present in the terminal sym-
pathetic neurons in two pools, a larger storage pool 
and a smaller labile pool. Bretylium tosylate does 
not affect the former, but its acute administration 
causes a sudden release of norepinephrine from 
the latter. This release of norepinephrine accounts 
for a number of the early effects of parenterally 
administered BT, such as the early transient hyper-
tension, enhanced automaticity, and increased con-
duction velocity. The initial positive inotropic effect 
( increased myocardial contractility) is largely, if not 
totally due to this norepinephrine release. Chronic 
bretylium therapy does, however, cause a super-
sensitivity to circulating and infused epinephrine 
and norepinephrine since BT blocks the sympa-
thetic neuronal uptake of these catecholamines, 
the major route of modulating the catecholamine-
receptor action. This same uptake mechanism also 
accounts for a number of bretylium drug interac-
tions as BT competes with tyramine, amphetamines, 
and metaraminol (Aramine®) for uptake. The tri-
cyclic anti-depressants also block BT uptake and 
antagonize its effect, as they do, too, for guane-
thidine (lsmelin@). 
Bretylium is excreted unchanged in the urine. 
Its serum half-life is unclear. Kuntzman et al. (13) 
studied four normal subjects and found a nonex-
ponential decline of serum levels with the rate of 
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disappearance quite rapid early (t112 = ± 1 hour) 
and somewhat slower later (t112 = ± 5 hours). Rom-
hilt and associates (22), using the serum method 
established by Kuntzman, studied eight patients. 
They found an exponential decline of serum levels 
with a tu2 = 10 hours (fig. 8). There was no apparent 
relationship between the t11 2 and the levels of 
BUN in this latter study, and personal communi-
cation failed to resolve this discrepancy. The t11 2 
value for bretylium tosylate may not be critical, 
however, since, as shown in figure 8, there is a 
temporal disparity between the serum levels and 
the antiarrhythmic efficacy. Bretylium tosylate 
may, therefore, be one of the so-called "hit-and-run" 
drugs (12). On the other hand, there appears to be 
an excellent correlation between the hypotensive 
effects and the serum levels of this "peripheral 
sympathetic blocker." This temporal dispersion of 
hypotensive and antiarrhythmic action prompted 
these authors (22) to suggest that BT's antiarrhyth-
mic effect may not be related to its action on the 
sympathetic neuron. 
There are both animal and human data to sug-
gest that other antiarrhythmic drugs antagonize the 
effects of bretylium. Bernstein and Koch-Weser (4) 
found that patients concurrently receiving other 
antiarrhythmic drugs were less likely to respond to 
BT, confirming the observations of Bacaner (2) in 
experimental animals. Therefore, it would appear 
wise to discontinue all other antiarrhythmics when 
initiating bretylium therapy. 
Bernstein and Koch-Weser (4) noted the fol-
lowing incidence of adverse effects: 
Side Effects of Short-Term Bretylium Therapy in 
30 Patients 
% 
Hypotension 63 
Hypertension 17 
Initial increase in arrhythmias 13 
Nausea or vomiting 10 
Involuntary head movements 3 
Headache 3 
In only one of the 19 patients with hypotension 
did the decline in blood pressure exceed 20 mm Hg. 
As these patients were recumbent and as the hypo-
tensive effect of BT is largely orthostatic, such re-
sults could be anticipated ( vide infra). Transient 
hypertension and transient enhanced automaticity 
(increase in arrhythmias) were surely related to 
the initial release of norepinephrine. Nausea and 
vomiting are rare with intramuscular administra-
tion, but common if bretylium is given intraven-
ously. 
Chronic oral administration commonly produces 
severe, persistent parotid pain during mastication. 
This pain is of sufficient magnitude to be the major 
cause for discontinuing chronic oral therapy. Pos-
tural hypotension is a problem early, but tolerance to 
this action develops fairly promptly. 
The clinical role of bretylium is still unclear, but 
the drug may find a place in the management of 
recurrent severe ventricular tachyarrhythmias, viz., 
ventricular tachycardia, and ventricular fibrillation. 
Bacaner reviewed 250 reported cases of ventric-
ular tachyarrhythmias ( 1). Eighty-five percent re-
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Fig. 8-Comparison of the onset and duration of action 
of bretylium, 4 mg/ kg, on PVC frequency and arterial 
pressure in relation to blood levels. On the average, hypo-
tensive effect was present in the first hour, when mean 
plasma concentration of bretylium was at its peak, and 
continued until the ninth hour after administration. By 
contrast 50% suppression of mean PVC frequency began 
at the sixth hour and continued until the 18th hour. The 
mean elimination half-life of bretylium was about 10 
hours. N refers to number of patients. (Reproduced by 
permission of the American Heart Association from Circu-
lation, 45 :804, 1972, and D. W. Romhilt ) . 
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sponded favorably. Romhilt et al. (22) continuously 
monitored eight patients with frequent premature 
ventricular contractions (fig. 9) . The effectiveness 
of bretylium tosylate, 4 mg per kg intramuscularly, is 
evident after a six-hour lag. Bernstein and Koch-
Weser (4) found an excellent response in 18 of 
30 patients with ventricular tachycardia unrespon-
sive to other drugs. Five patients had a partial re-
sponse and in seven, no response was evident. 
Those failing to respond were more often receiving 
other antiarrhythmic drugs concurrently and were 
more likely to have had the arrhythmia for a longer 
period of time. These authors rightly caution against 
an over zealous interpretation of these data, noting 
that had these patients been first treated with bre-
tylium, the fai lures could well have responded to 
whatever the second drug might have been. 
One negative report is noteworthy. Taylor 
et al. (24) studied 101 patients during acute myo-
cardial infarction. Sixty-three patients received 
bretylium, 300 mg IM every 6 hours. In 25 of 
the 63, therapy was discontinued because of ad-
verse effects, four due to nausea and vomiting and 
21 due to hypotension. In these 21 patients, blood 
1000 
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Fig. 9-Mean PVC frequency during treatment days com-
pared with control days. There was 50% supression of 
mean PVC frequency in the second and third 6-hour in-
tervals following bretylium 4 mg/ kg (solid bars) , while no 
suppression was seen after 2 mg/ kg ( shaded bars). Control 
days are shown in stippled bars. N refers to number of 
patients. On day 1, data were not obtained in one patient 
during the first 12 hours due to recording-equipment failure. 
(Reproduced by permission of the American Heart As-
sociation from Circulation, 45: 805 , 1972, and D. W. Rom-
hilt). 
pressure averaged 65/ 40 mm Hg, a marked degree 
of hypotension for patients with acute infarction. It 
is likely that the unstable state of the circulation in 
such patients and their use of bedside commodes, 
thus enhancing orthostasis, accounts for the strikingly 
higher incidence of significant degrees of hypoten-
sion than those noted in the table above. Furthermore, 
among those who continued BT therapy, there was 
no decrease in ventricular arrhythmias. Supraven-
tricular arrhythmias, however, were less in the 
treated group. Again, one patient died in each of the 
treated and control groups. 
Finally, the role of bretylium tosylate in the 
management of digitalis-induced ventricular tachy-
arrhythmias should be considered. Our group (20) 
infused ouabain in a group of ten dogs. In half, the 
ouabain was continued until stable ventricular tachy-
cardia was established. Bretylium was then given in 
incremental doses, beginning with 5 mg per kg and 
increasing to 40 mg per kg total dose. In every dog, 
the ventricular tachycardia not only persisted, but 
indeed, the ventricular rate accelerated. Further-
more, when the ouabain infusion was stopped at 
the time frequent ventricular premature contrac-
tions had occurred, bretylium, in each of the five 
dogs, promptly induced ventricular tachycardia (fig. 
10). This augmentation of automaticity by BT was 
also noted by Kleiger and Shander (11). They pro-
duced ventricular tachycardia in dogs with acetyl-
strophanthidin (another cardiac glycoside). When 
the tachycardia had subsided spontaneously after 
cessation of the glycoside, they administered brety-
lium and a recurrence of the ventricular tachycardia 
ensued. Both of these animal studies were com-
pleted before the time of maximal antiarrhythm ic 
efficacy of BT, but they indicate the potential dan-
ger during the period of initiation of such therapy. 
In conclusion, time and space have not al-
lowed a classical pharmacological discussion of these 
four important antiarrhythmic drugs. In order to 
use a drug rationally so as to obtain a maximum 
efficacy: toxicity ratio, one must understand the 
drug's absorption, its route and mechanism of bio-
transformation, and its effective half-life. Such data 
are available for the antiarrhythmic drugs. 
Where the achievement of one's therapeutic 
goal is so readily measurable, as it is with antiar-
rhythmic drugs, we must demand of ourselves a 
more knowledgeable and rational therapeutic ap-
proach. 
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DOG #6 
CONTROL 
'-
AFTER OUABAIN 70.,ug/Kg 
AFTER BRETYLI UM 5mg/Kg 
AFTER BRETYLIUM 35mg/Kg 
Fig. 10-0uabain was given to this dog until frequent 
premature ventricular contractions developed. Treatment, 
then, with bretylium induced ventricular tachycardia. 
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Dr. Surawicz: I use quinidine less, and some people 
have stopped using it. This is actually the only true 
antiarrhythmic drug because it is the only drug that 
will reasonably consistently convert atrial fibrilla-
tion to sinus rhythm. As Dr. Hoffman pointed out, its 
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effect on conduction would have predictable effects 
on the electrocardiogram in terms of prolongation 
of the QRS complex and the P-R interval, and 
with increasing concentration of the drug, which is 
increasing the dose, we have evidence of increasing 
EFFECT OF DRUG ON HEART 
Name of Drug 
Quinidine 
Procainamide 
(Pronestyl ®l 
Lidocaine 
(Xylocaine ®l 
Propranolol 
(lnderal ®) 
Diphenylhydantoin 
(Dilan tin ®) 
Bretylium 
(Daren thin®> 
Automaticity 
Atrium Ventricle 
0 
Initialj 
l 
l 
Initialj 
thenl(?) 
Conduction 
Velocity 
l 
l 
0 
l 
i 
Initialj 
then O 
Refractory 
Period 
i 
i 
l 
l 
Initiall 
thenj 
Inotropic 
State 
l 
0 
H 
0 
Initialj 
Autonomic 
Effects 
Vagolytic 
Vagolytic 
0 
Beta-adrenergic 
Blocking 
0 
NE Release 
Followed by 
Sympath Block 
Therapeutic 
Plasma Levels 
µg / ml 
3-6 
4-8 
2-5 
.05-.15 
6-18 
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prolongation of P-R and ORS intervals. This is a 
dose related toxicity that we can avoid by keeping 
our doses down. Dr. Wasserman discussed the quin-
idine induced ventricular fibrillation and pointed out 
that this is not necessarily a dose related effect. 
This occurs when the concentrations are therapeutic 
and the ORS interval is not widened and the P-R 
is not prolonged. Therefore, we have no warning, 
and that is much more frightening because this 
cannot be avoided. Now, does that mean that we 
should stop using quinidine? I, of course, asked 
that question and observed some quinidine syncope, 
the same kind of record as was shown from Dr. 
Selzer's and Dr. Wray's paper. Then I reviewed all 
available data on quinidine toxicity and came to 
the conclusion that all published reports that I 
have been able to review showed three things: 
firs t, all people had severe heart disease; second, 
all people were treated with digitalis; and third, in 
spite of quinidine syncope not being dose related, 
they all received more than 1.2 g of quinidine per 
day. I concluded that I have not had any evidence 
that lower doses will induce fibrillation. On that 
basis I still use quinidine, and I wonder whether you 
would like to comment on that. 
Dr. Wasserman: Yes. In some of the cases it is clear 
that preceding the fibrillation there was prolongation 
Plasma Peak Effect Time 
Half-Life 
Biotransformation t 1/ 2 p.o. I.V. 
Renal 10-50% 4- 6 hr. 2- 4 hr. 5 min. 
( lif jurine pH) 
Liver 
Renal 60% 3- 4 hr. l hr. Stat 
(lif j urine pH) 
Liver 2 hr. Stat 
Liver ± 3 hr. few hrs. 10 min. 
Liver 18- 24 hr. 1- 2 hr. 5 min. 
average 
Renal ±10 hr. hrs. 15 min. 
of the 0-T interval ; thus, whether or not this is 
predictable in the majority of cases, I do not know. 
It certainly would be in some, and it is for this 
reason that we are monitoring. I can tell you about 
a case in which a young lady who had no heart 
disease whatsoever was erroneously treated for 
VPC's which I am sure in retrospect were due to 
alcoholism. In the absence of digitalis and with 
standard doses she developed this syndrome. She 
was shocked 20 or 30 times with typical findings . 
We did not have a quinidine level in her, but her 
renal function was normal , her heart was normal, 
and we simply stopped the drug. Within the usual 
six hour period, actually four hours, she stopped 
having ectopic activity and stopped her recurrent 
bouts of ventricular fibrillation. Subsequently, we 
have found normal and even low levels of serum 
quinidine in patients exhibiting quinidine syncope, 
including cases where syncope followed a single 
usual initial dose of quinidine. 
Questioner: Did your alcoholic patient have hypo-
kalemia? 
Dr. Wasserman: No, she did not. As a matter of 
fact, she came in with pelvic inflammatory disease 
but unfortunately was seen by a medical intern who 
was certain that he knew how to take care of her 
Dosage 
p.o. 
(gm) 
0 .4 X 1; 
0.2- 0.4q 
6 hr. 
1.0 X 1; 
0 . Sq 3 hr. 
.04 X l; 
.Ol-.03q 
6 hr. ? 
1.0 first day 
0.5 next day 
then 0.4/ day 
.3- . 6q 
8-12 hr. 
I.V. 
(mg) 
25 / min . to 
1000 
50 / min. to 
1-2,000 
Adverse Effects 
(See Heart Effects) 
"Syncope"; Shoq:k; Hemolysis; 
Thrombocytopenia; G-l Sx; 
Paralys is; Cinchonism 
Lupus; Shock; ? Syncop~; 
Agranulocytosis; G-l Sx; 
Psychosis; Paralysis 
50-100 Stat Twitching, Seizures; 
1-4/ min. CNS Depression; Shock 
0. I / min. to Heart failure; Bronchospasm; 
10 Hypoglycemic Unresponsiveness; 
Rash; G-l Sx 
50- lOOmg 
5/ min. to 
1,000 
Ataxia ; Sedation; Gums; 
Lymphoma: Lupus ; Rash; 
Folate Def; Hepatitis; 
Osteomalacia; Thyroiditis 
Nystagmus 
4-5 mg / Kg Initial Tachycardia; 
Postural Hypotension; 
Parotid pain; 
Vomiting I.V. 
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Addendum 2 
DIPHENYLHYDANTOIN DRUG INTERACTIONS 
I. DRUGS LEADING TO INCREASED DPH EFFECT AND TOXICITY 
DRUGS 
A. Bishydroxycoumarin (Dicumarol ®> 
B. Disulfiram (Antabuse ®) 
C. Isoniazid 
slow-inactivators 
D . PAS 
E. Phenylbutazone (Butazolidin ®> 
F. Phenyramidol (Analexin ®) 
G. Sulfaphenazole (Sulfabid ®) 
and Sulthiame (Ospolot ®) 
H. Salicylates 
I. Chloramphenicol 
J. Benzodiazepines 
K. Methylphenidate (Ritalin®> 
II. DRUGS LEADING TO DECREASED DPH EFFECT AND TOXICITY 
A. Phenobarbital 
B. Amphetamines 
C. Alcohol 
III. DPH'S EFFECT ON OTHER DRUGS 
MECHANISM 
Inhibition of liver metabolism 
Inhibition of liver metabolism 
Not definite- probably inhibition of liver 
metabolism 
Unknown- Possibly due to its increased 
blood levels of concommitant INH 
Binding displacement of DPH 
Inhibition of liver metabolism 
Unknown 
Binding displacement of DPH 
Inhibition of liver metabolism 
Unknown 
Not definite- probably inhibition of liver 
metabolism 
Increased hepatic microsomal metabolism 
Decreased absorption of DPH 
Increased liver metabolism of DPH 
DRUGS 
A. Coumarin Anticoagulants 
B. Corticosteroids 
C. Methotrexate 
D . VitaminD 
EFFECT 
Enhancement 
Inhibition 
Enhancement 
Inhibition 
MEC HANISM 
Not definite- probably binding displacement 
Increased microsomal metabolism 
Binding displacement 
Increased liver metabolism of Vit. D 
VPC's. Of course when she developed the first 
episode of ventricular fibrillation, he concluded that 
he simply had not given her enough. She received 
two doses of quinidine, but that was all . 
Dr. Dreifus: I too use quinidine. I just want to 
mention two things. The first point Dr. Surawicz 
already inferred was low potassium, and this seems 
to be one of the settings in which I have seen this 
repetitive ventricular tachycardia with quinidine 
and with other antiarrhythmic drugs that prolong 
Q-T intervals. The second point, which is much more 
serious, is acute coronary insufficiency with very 
long Q-T intervals. It is usually seen on the basis 
of sinus bradycardia. These patients do worse with 
quinidine or procainamide because you may move 
the premature systole into the long Q-T interval. 
The VPC will bisect the T wave, and then ven-
tricular fibrillation or runs of ventricular tachycardia 
occur. Actually, the only way to deal with such 
patients is to pace them. The reason I wanted to 
mention this is, if patients at high risk were on a 
prophylactic agent and quinidine or a congener 
of quinidine was one on these agents, the patients 
who were tending to develop long Q-T intervals with 
their bouts of coronary insufficiency might be more 
vulnerable to sudden death. This is a very serious 
problem, and I think when you use quinidine you 
have to take all these facts into consideration if 
you want to avoid mistakes. 
Dr. Dreifus: I would like to ask Dr. Wasserman if 
he feels that bretylium has any membrane effects 
as an antiarrhythmic agent. 
Dr. Wasserman: Yes. The problem of course has 
been to forget the initial articles, all of which were 
merely reflecting the release norepinephrine. I 
think it is quite clear that it does have direct myo-
cardial effects. It certainly does so in the absence 
of norepinephrine depleted by pretreatment re-
serpine or guanethidine, and it has effects which 
differ from guanethidine in terms of the ventricular 
fibrillation threshold which suggests that it is not 
simply the depletion of catecholamines. Thus, I 
think it clearly must have some effect. I think 
its role is not yet clear, and I think we need to 
know more about it before we can use it wisely. 
